FMO2

Across TCGA pan-cancer cohorts, FMO2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FMO2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where FMO2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FMO2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where FMO2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FMO2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−1.287	<.001	9	view →
LUAD	Female	II,III,IV	−1.281	<.001	9	view →
HNSC	All	III,IV	−0.568	.010	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

FMO2–LSCC

Open the LSCC breakdown →